Literature DB >> 14999382

[Hepatitis (Hep-Net) competence network].

H Wedemeyer1, S Meyer, M P Manns.   

Abstract

In Germany almost 1 million people are affected by chronic viral hepatitis. Despite of the improved therapy options for the treatment of hepatitis B and C, several questions regarding epidemiology, pathophysiology and therapy are still unclear. Vaccines against hepatitis C and D viruses are still not available. Additionally, many patients and their relatives need information about infectiosity, course of the disease and therapy options. By the integration of doctors' practices and patient advocacy groups, Hep-Net aims at the educational information on the infection and tries to give access to qualified therapy strategies for all patients with an indication for therapy. After 18 months the Hep-Net Homepage already shows more than 9000 hits per day. Consultation hours via telephone, email-services and numerous activities in cooperation with the Deutsche Leberhilfe e.V. are highly frequented. In the Hep-Net study-house high-standard clinical studies with first successful results are centrally organized. Further, basic questions in the fields of epidemiology, virology and immunology are processed in cooperative research projects within the network.

Entities:  

Mesh:

Year:  2004        PMID: 14999382     DOI: 10.1007/s00108-004-1154-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  15 in total

Review 1.  Hepatitis D: virology, clinical and epidemiological aspects.

Authors:  M Rizzetto
Journal:  Acta Gastroenterol Belg       Date:  2000 Apr-Jun       Impact factor: 1.316

2.  Paroxetine for the prevention of depression induced by interferon alfa.

Authors:  M R Kraus; A Schäfer; M Scheurlen
Journal:  N Engl J Med       Date:  2001-08-02       Impact factor: 91.245

Review 3.  Management of hepatitis B: 2000--summary of a workshop.

Authors:  A S Lok; E J Heathcote; J H Hoofnagle
Journal:  Gastroenterology       Date:  2001-06       Impact factor: 22.682

Review 4.  Course and outcome of hepatitis C.

Authors:  Jay H Hoofnagle
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

Review 5.  Therapy of acute hepatitis C.

Authors:  Alfredo Alberti; Silvia Boccato; Alessandro Vario; Luisa Benvegnù
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

6.  Treatment of acute hepatitis C with interferon alfa-2b.

Authors:  E Jaeckel; M Cornberg; H Wedemeyer; T Santantonio; J Mayer; M Zankel; G Pastore; M Dietrich; C Trautwein; M P Manns
Journal:  N Engl J Med       Date:  2001-11-15       Impact factor: 91.245

7.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

8.  Prevalence of markers of hepatitis B in the adult German population.

Authors:  W Jilg; B Hottenträger; K Weinberger; K Schlottmann; E Frick; A Holstege; J Schölmerich; K D Palitzsch
Journal:  J Med Virol       Date:  2001-02       Impact factor: 2.327

9.  Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients.

Authors:  David Bernstein; Leah Kleinman; Chris M Barker; Dennis A Revicki; Jesse Green
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

Authors:  J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.